BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-08
169 industry Phase 2/3 trial readout(s) and 32 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-08 est. | P2 | VivaTech International, Inc. | NCT02844738 Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder | Osteoarthritis | recruiting | 4000 |
| 2026-08 est. | P2 | VivaTech International, Inc. | NCT02844751 Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee | Osteoarthritis | recruiting | 4000 |
| 2026-08 est. | P2 | VivaTech International, Inc. | NCT02844764 Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip | Osteoarthritis | recruiting | 4000 |
| 2026-08 est. | P3 | AbbVie ABBV | NCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Partici | Multiple Myeloma | active not recruiting | 265 |
| 2026-08 est. | P1/P2 | AtlasMedx, Incorporated | NCT04503265 A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Advanced Malignant Neoplasm; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency; Pro | recruiting | 122 |
| 2026-08 est. | P1/P2 | Allist Pharmaceuticals, Inc. | NCT05009329 A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China | NSCLC; Solid Tumor | active not recruiting | 315 |
| 2026-08 est. | P1/P2 | BicycleTx Limited | NCT05163041 Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Advanced Solid Tumor | active not recruiting | 200 |
| 2026-08 est. | P1/P2 | AB Science | NCT05211570 AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse; Myelodysplastic Syndrome Acut | recruiting | 78 |
| 2026-08 est. | P1/P2 | Treadwell Therapeutics, Inc | NCT05251714 CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | Advanced Solid Tumor; Breast Cancer | active not recruiting | 44 |
| 2026-08 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05351788 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | Non-small Cell Lung Cancer | recruiting | 110 |
| 2026-08 est. | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT05490472 JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Solid Tumors; ER+ Breast Cancer; Triple Negative Breast Cancer, TNBC; ARID1A Gene Mutation; Small Ce | recruiting | 102 |
| 2026-08 est. | P2 | CrystalGenomics, Inc. | NCT05841472 Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non- | Non Squamous Non Small Cell Lung Cancer | recruiting | 60 |
| 2026-08 est. | P3 | CELL Technologies Inc. | NCT06216028 Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee Osteoarthritis | Knee Osteoarthritis; Musculoskeletal Diseases | not yet recruiting | 374 |
| 2026-08 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06343948 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Canc | HR+HER2- Breast Cancer | active not recruiting | 383 |
| 2026-08 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06382116 A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) | Non-small Cell Lung Cancer | active not recruiting | 432 |
| 2026-08 est. | P3 | Yantai LNC Biotechnology Singapore PTE. LTD. | NCT06416852 Clinical Study of 18F-Alfatide Injection PET/CT | Non-Small Cell Lung Cancer NSCLC | not yet recruiting | 428 |
| 2026-08 est. | P2 | Cornerstone Pharmaceuticals CLM | NCT06518538 Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer | Pancreatic Cancer Stage IV | withdrawn | |
| 2026-08 est. | P2 | Veradermics, Inc. MANE | NCT06527365 Safety and Efficacy of VDPHL01 in Males and Females With AGA | Androgenetic Alopecia; AGA; Male Pattern Baldness | active not recruiting | 70 |
| 2026-08 est. | P3 | Cerevance | NCT06553027 To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | Parkinson Disease | active not recruiting | 330 |
| 2026-08 est. | P3 | Ensysce Biosciences ENSC | NCT06602271 PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) | Postoperative Pain, Acute | recruiting | 320 |
| 2026-08 est. | P2 | Tasly Biopharmaceuticals Co., Ltd. | NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervic | not yet recruiting | 120 |
| 2026-08 est. | P3 | Shanghai Mabgeek Biotech.Co.Ltd | NCT06779136 Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis | Prurigo Nodularis | recruiting | 160 |
| 2026-08 est. | P2 | Clinique Ovo | NCT06997900 Menopur And Rekovelle Combination Study Version 2.0 | IVF; Controlled Ovarian Simulation; Fertility Disorders | recruiting | 200 |
| 2026-08 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07056439 Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients | PET Imaging in Patients With Prostate Cancer | not yet recruiting | 50 |
| 2026-08 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT07110571 A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer | Gastric Cancer; Gastroesophageal-junction Cancer | recruiting | 200 |
| 2026-08 est. | P3 | Pharmbio Korea Co., Ltd. | NCT07114406 A Study to Evaluate Safety and Efficacy of PBK_M2502 | Intestinal Disease; Colonic Diseases; Gastrointestinal Disease; Digestive System Disease | not yet recruiting | 110 |
| 2026-08 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT07229937 A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia | Hyperlipidemia | recruiting | 189 |
| 2026-08 est. | P3 | Mirum Pharmaceuticals, Inc. MIRM | NCT07298330 A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) | Chronic Hepatitis D Infection | active not recruiting | 80 |
| 2026-08 est. | P3 | Invivyd, Inc. IVVD | NCT07298434 Study of VYD2311 for the Prevention of COVID-19 | COVID-19 | active not recruiting | 1770 |
| 2026-08 est. | P2 | Rebel Medicine Inc | NCT07574385 Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy | Hallux Valgus; Bunionectomy | recruiting | 60 |
| 2026-08 est. | P2 | Shanghai QuietD Biotechnology Co., Ltd. | NCT07581210 Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy | Acute Ischemic Stroke | recruiting | 120 |
| 2026-08-01 est. | P1/P2 | Bridge Biotherapeutics, Inc. | NCT05920135 First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI | EGFR Mutant Advanced Non-Small Cell Lung Cancer | active not recruiting | 24 |
| 2026-08-01 est. | P1/P2 | OncoResponse, Inc. | NCT06090266 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Cancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanom | recruiting | 168 |
| 2026-08-01 est. | P3 | Santen SAS | NCT06514612 LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharopto | Acquired Blepharophimosis | recruiting | 234 |
| 2026-08-01 | P1/P2 | Implicit Bioscience | NCT06678074 Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI | STEMI; STEMI (ST Elevation MI); STEMI - ST Elevation Myocardial Infarction (MI); Stent Implantation | completed | 7 |
| 2026-08-01 est. | P3 | Gan & Lee Pharmaceuticals. | NCT06767735 A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM) | Diabetes | active not recruiting | 580 |
| 2026-08-01 est. | P3 | Jiangxi Kvvit Pharmaceutical Co., Ltd. | NCT07113392 A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension | Influenza | not yet recruiting | 144 |
| 2026-08-01 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07469800 Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity | Overweight; Obesity; Hypertensive | recruiting | 336 |
| 2026-08-01 est. | P3 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | NCT07473427 Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children | Varicella (Chickenpox); Varicella Immunisation | not yet recruiting | 300 |
| 2026-08-02 est. | P2 | Ausper Biopharma Co., Ltd. | NCT06829329 Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB) | Chronic Hepatitis B | active not recruiting | 105 |
| 2026-08-03 | P2 | Merck Sharp & Dohme LLC MRK | NCT06465186 A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD; Metabolic Dysfunction-associ | completed | 85 |
| 2026-08-03 | P2 | Eli Lilly and Company LLY | NCT06598943 A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis; Ulcerative Colitis Chronic | active not recruiting | 143 |
| 2026-08-03 est. | P2 | Catalysis SL | NCT07179237 Efficacy of Carminal in Helicobacter Pylori Gastritis | H Pylori Gastritis; H Pylori Infection; H Pylori Eradication; Gastritis Associated With Helicobacter | recruiting | 80 |
| 2026-08-03 | P3 | Merck Sharp & Dohme LLC MRK | NCT07216482 A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) | Hyperlipidemia | completed | 996 |
| 2026-08-03 | P2 | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | NCT07807007 Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma | Asthma | completed | 150 |
| 2026-08-04 | P2/P3 | Genzyme, a Sanofi Company | NCT03974113 Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B | Hemophilia | completed | 32 |
| 2026-08-04 | P3 | Celldex Therapeutics CLDX | NCT06455202 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Chronic Spontaneous Urticaria | active not recruiting | 976 |
| 2026-08-05 | P2 | Boehringer Ingelheim | NCT06241560 A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood | Idiopathic Pulmonary Fibrosis | completed | 20 |
| 2026-08-05 | P2 | Brii Biosciences Limited | NCT06491563 Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) | For Treatment of Chronic Hepatitis B Virus Infection | completed | 150 |
| 2026-08-05 | P2 | Sanofi SNY | NCT06557772 A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease | Coeliac Disease; Celiac Disease | active not recruiting | 229 |
| 2026-08-05 | P2/P3 | Glycomine, Inc. | NCT06892288 A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG | Phosphomannomutase 2 Deficiency; PMM2-CDG | active not recruiting | 50 |
| 2026-08-05 | P2 | Rapport Therapeutics Inc. RAPP | NCT07046494 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder | Bipolar 1 Disorder | completed | 253 |
| 2026-08-05 | P3 | Merz Aesthetics GmbH | NCT07210463 A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU) | Neuromuscular Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Acetylcholin | active not recruiting | 300 |
| 2026-08-05 | P3 | RDC Clinical Pty Ltd | NCT07241377 A Study in Healthy Adults to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source and Placebo | Absorption of Omega-3; Omega-3 Supplementation; Healthy Participants | completed | 120 |
| 2026-08-06 | P2 | GlaxoSmithKline | NCT06213506 A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infan | Salmonella Infections | completed | 180 |
| 2026-08-06 | P2 | BioVie Inc. BIVI | NCT06847191 NE3107 in Adults With Neurological Symptoms of Long COVID | Long COVID | completed | 203 |
| 2026-08-06 | P2 | Sanofi SNY | NCT06867094 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis | Colitis Ulcerative | terminated | 170 |
| 2026-08-06 | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07357831 A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects | Plaque Psoriasis | completed | 539 |
| 2026-08-07 | P3 | Incyte Corporation INCY | NCT06832618 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 159 |
| 2026-08-09 | P3 | UCB Biopharma SRL | NCT04436640 A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondyli | Axial Spondyloarthritis; Ankylosing Spondylitis; r-axSpa; Nr-axSpa | completed | 508 |
| 2026-08-10 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04626479 Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | Carcinoma, Renal Cell | completed | 393 |
| 2026-08-10 | P3 | AstraZeneca AZN | NCT05211895 A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | Non-Small Cell Lung Cancer | active not recruiting | 791 |
| 2026-08-10 | P3 | AstraZeneca AZN | NCT05267613 Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. | Erosive Esophagitis | completed | 53 |
| 2026-08-10 est. | P1/P2 | ModernaTX, Inc. | NCT06147856 A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria | Phenylketonuria | withdrawn | |
| 2026-08-10 | P2 | BioArctic AB | NCT06671938 Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy | Parkinson Disease; Multiple System Atrophy | completed | 38 |
| 2026-08-10 | P2 | AstraZeneca AZN | NCT06681324 Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy | Crohn's Disease | active not recruiting | 24 |
| 2026-08-10 | P2 | Ascletis Pharma (China) Co., Limited | NCT07321678 A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus | T2DM (Type 2 Diabetes Mellitus) | completed | 100 |
| 2026-08-11 | P1/P2 | Bristol-Myers Squibb BMY | NCT06035497 A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas i | Relapsed or Refractory T-cell Lymphomas | active not recruiting | 83 |
| 2026-08-11 | P2 | EMD Serono Research & Development Institute, Inc. | NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | Ovarian Cancer | completed | 63 |
| 2026-08-11 est. | P2 | ZyVersa Therapeutics, Inc. | NCT06489340 P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease | Diabetic Kidney Disease | withdrawn | |
| 2026-08-11 | P3 | HALEON HLN | NCT07215767 Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice | Dentin Hypersensitivity | completed | 688 |
| 2026-08-12 | P1/P2 | Alpine Immune Sciences Inc, A Subsidiary of Vertex | NCT05757570 An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) | Idiopathic Thrombocytopenic Purpura; Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia; Cold | completed | 30 |
| 2026-08-12 | P3 | DualityBio Inc. | NCT06018337 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Metastatic Breast Cancer | active not recruiting | 541 |
| 2026-08-12 | P3 | Merck Sharp & Dohme LLC MRK | NCT06052059 A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) | Ulcerative Colitis | active not recruiting | 1109 |
| 2026-08-12 | P3 | Amgen AMGN | NCT06088199 A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis | Plaque Psoriasis | completed | 51 |
| 2026-08-12 | P2 | argenx ARGX | NCT06441682 A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | terminated | 60 |
| 2026-08-12 | P3 | Celldex Therapeutics CLDX | NCT06445023 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | active not recruiting | 963 |
| 2026-08-12 | P2 | EnnovaBio | NCT06708260 A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects With DME | Diabetic Macular Edema (DME) | completed | 60 |
| 2026-08-12 | P2 | Pharming Technologies B.V. PHAR | NCT06897358 Leniolisib for Immune Dysregulation in CVID | Common Variable Immunodeficiency (CVID) | completed | 27 |
| 2026-08-12 | P3 | Akebia Therapeutics AKBA | NCT06901505 To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis | Anemia of Chronic Kidney Disease | completed | 353 |
| 2026-08-12 | P3 | pH-D Feminine Health LLC | NCT07109869 Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis | Vulvovaginal Candidiases; Vulvovaginal Candidiasis, Genital; Vulvovaginal Candidiasis (VVC) | completed | 333 |
| 2026-08-13 | P1/P2 | Hoffmann-La Roche | NCT03157635 Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglob | Paroxysmal Hemoglobinuria, Nocturnal | completed | 59 |
| 2026-08-13 | P3 | BrightGene Bio-Medical Technology Co., Ltd. | NCT06716203 A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Type 2 Diabetes Mellitus (T2DM) | completed | 227 |
| 2026-08-13 | P3 | Definium Therapeutics US, Inc. DFTX | NCT06809595 A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | Generalized Anxiety Disorder | active not recruiting | 245 |
| 2026-08-13 | P2 | Zealand Pharma ZEAL.CO | NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) | Overweight; Type 2 Diabetes; Obesity | completed | 221 |
| 2026-08-13 est. | P2 | Hinova Pharmaceuticals Inc. | NCT07308548 A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH ) | NAFLD (Non-alcoholic Fatty Liver Disease) | recruiting | 80 |
| 2026-08-14 est. | P1/P2 | Healeon Medical Inc | NCT02946658 Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders | Lung Disease | suspended | 100 |
| 2026-08-14 | P1/P2 | TCM Biotech International Corp. | NCT03812874 A Study of PTX-9908 Injection for Non-resectable HCC With TACE | Carcinoma, Hepatocellular | withdrawn | |
| 2026-08-14 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06507436 The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | completed | 127 |
| 2026-08-14 | P2 | Boehringer Ingelheim | NCT06926660 A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease | Chronic Kidney Disease | completed | 492 |
| 2026-08-14 | P2 | AstraZeneca AZN | NCT07143604 A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18. | Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 33 |
| 2026-08-14 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07372924 A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU) | Abirritation in the ICU | completed | 121 |
| 2026-08-15 est. | P2 | Telavant, Inc. | NCT05471492 Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease | Crohn Disease | withdrawn | |
| 2026-08-15 | P3 | Invivyd, Inc. IVVD | NCT07655180 Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine | COVID-19 | completed | 210 |
| 2026-08-16 est. | P2 | JenKem Technology Co., Ltd. | NCT06595186 JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) | Glioblastoma Multiforme (GBM) | recruiting | 25 |
| 2026-08-17 | P2 | AbbVie ABBV | NCT03339128 Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children | Irritable Bowel Syndrome | completed | 272 |
| 2026-08-17 | P3 | AstraZeneca AZN | NCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | Metastatic Non-small Cell Lung Cancer | active not recruiting | 895 |
| 2026-08-17 | P3 | Neumora Therapeutics, Inc. NMRA | NCT06029439 Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Major Depressive Disorder | terminated | 904 |
| 2026-08-17 | P2 | NeuroPro Therapeutics, Inc. | NCT06769659 A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures | Epilepsy, Generalized; Epilepsy, Absence | completed | 14 |
| 2026-08-17 | P2 | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | NCT07016412 Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) | Chronic Obstructive Pulmonary Disease | completed | 497 |
| 2026-08-18 | P2 | Janssen Sciences Ireland UC | NCT02494986 A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies | Human Immunodeficiency Virus Type 1 | completed | 48 |
| 2026-08-18 est. | P3 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | NCT06519370 FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | Triple Negative Breast Cancer | active not recruiting | 350 |
| 2026-08-18 | P3 | Genmab GMAB | NCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Platinum-resistant Ovarian Cancer | active not recruiting | 584 |
| 2026-08-18 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT06864169 A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) | Gastrointestinal Cancer | active not recruiting | 160 |
| 2026-08-18 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07330934 A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | terminated | 18 |
| 2026-08-19 | P2 | Novartis Pharmaceuticals NVS | NCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration | Age-Related Macular Degeneration | completed | 168 |
| 2026-08-19 | P3 | ViiV Healthcare | NCT06694805 A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 | HIV Infections | active not recruiting | 326 |
| 2026-08-20 | P3 | Ardelyx ARDX | NCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years | Irritable Bowel Syndrome With Constipation (IBS-C) | completed | 180 |
| 2026-08-20 | P3 | Sol-Gel Technologies, Ltd. SLGL | NCT06050122 Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome | Gorlin Syndrome | completed | 113 |
| 2026-08-20 | P3 | Hansoh BioMedical R&D Company | NCT06498479 ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | Small Cell Lung Cancer | completed | 461 |
| 2026-08-21 | P2 | Endeavor Biomedicines, Inc. | NCT06422884 A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) | Idiopathic Pulmonary Fibrosis; Progressive Fibrosing Interstitial Lung Disease | completed | 213 |
| 2026-08-21 | P2 | NodThera Ltd. (a Rezera company) | NCT07220629 Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) | Obesity | completed | 82 |
| 2026-08-21 | P3 | AbbVie ABBV | NCT07284381 A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participan | Dry Eye Disease | completed | 261 |
| 2026-08-22 est. | P2 | Bazelet Nehushtan LtD. | NCT06542445 The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD | Attention Deficit Hyperactivity Disorder (ADHD) | unknown | 120 |
| 2026-08-24 est. | P3 | Alexion Pharmaceuticals, Inc. | NCT05389449 A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | Paroxysmal Nocturnal Hemoglobinuria | active not recruiting | 80 |
| 2026-08-24 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in A | Resectable Non-small Cell Lung Cancer | active not recruiting | 195 |
| 2026-08-24 | P2 | GlaxoSmithKline | NCT07204964 A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above | Influenza, Human | completed | 971 |
| 2026-08-25 | P1/P2 | Hoffmann-La Roche | NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration | Macular Degeneration | completed | 177 |
| 2026-08-25 est. | P2 | BPGbio | NCT04752813 A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) | Glioblastoma; Glioblastoma Multiforme | active not recruiting | 50 |
| 2026-08-25 | P2 | Hoffmann-La Roche | NCT05634499 A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer | Endometrial Cancer | completed | 33 |
| 2026-08-25 | P1/P2 | Crinetics Pharmaceuticals Inc. | NCT05804669 A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome | Cushing Syndrome; Cushing Disease; Ectopic ACTH Syndrome | completed | 19 |
| 2026-08-25 | P3 | BrightGene Bio-Medical Technology Co., Ltd. | NCT06716216 A Study of BGM0504 in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | completed | 553 |
| 2026-08-25 | P3 | PDS Biotechnology Corp. PDSB | NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer; HPV Positive Oropharyngeal Squamous | terminated | 12 |
| 2026-08-25 | P3 | Pfizer PFE | NCT07543380 A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. | Respiratory Syncytial Virus (RSV) | completed | 130 |
| 2026-08-26 | P2 | UCB BIOSCIENCES, Inc. | NCT03845712 An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency | Thymidine Kinase 2 Deficiency | completed | 47 |
| 2026-08-26 | P3 | Pfizer PFE | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatment | Multiple Myeloma | recruiting | 492 |
| 2026-08-26 | P3 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT06468956 Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis | Moderate to Severe Atopic Dermatitis | completed | 652 |
| 2026-08-26 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06577376 A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; | not yet recruiting | 252 |
| 2026-08-26 | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07473960 IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | completed | 198 |
| 2026-08-26 est. | P2 | ParagonClinicals Inc. | NCT07627815 Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID | Long COVID | recruiting | 82 |
| 2026-08-27 est. | P1/P2 | Blue Earth Therapeutics Ltd | NCT05413850 Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; mCRPC; Urogenital Neoplasms; Prost | recruiting | 82 |
| 2026-08-27 | P2 | Syndax Pharmaceuticals SNDX | NCT06132256 MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | completed | 145 |
| 2026-08-27 | P1/P2 | Chiesi Farmaceutici S.p.A. | NCT06166056 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated | Bronchiectasis | completed | 108 |
| 2026-08-27 | P3 | Eli Lilly and Company LLY | NCT06260722 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 | Diabetes Mellitus, Type 2 | active not recruiting | 1250 |
| 2026-08-28 | P2/P3 | Hutchmed HCM | NCT05522231 Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | Advanced Renal Cell Carcinoma | completed | 265 |
| 2026-08-28 | P3 | Arcus Biosciences, Inc. RCUS | NCT05568095 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That C | Advanced Upper Gastrointestinal Tract Adenocarcinoma | completed | 1040 |
| 2026-08-29 est. | P2/P3 | Panbela Therapeutics, Inc. | NCT05254171 Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV | recruiting | 600 |
| 2026-08-29 | P3 | Bracco Diagnostics, Inc | NCT06400004 Lumason® Infusion vs. Bolus Administrations | Heart Diseases | recruiting | 106 |
| 2026-08-30 | P2 | OncoC4, Inc. | NCT05446298 ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian T | active not recruiting | 58 |
| 2026-08-30 est. | P1/P2 | Fujian Haixi Pharmaceuticals Co., Ltd. | NCT06220318 Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors | Solid Tumor | active not recruiting | 155 |
| 2026-08-30 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06425341 A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in | Chronic Hepatitis B | recruiting | 369 |
| 2026-08-30 est. | P3 | Keymed Biosciences Co.Ltd | NCT06495229 Study of CM310 in Adolescent Subjects With Atopic Dermatis | Atopic Dermatitis | active not recruiting | 180 |
| 2026-08-30 | P1/P2 | Implicit Bioscience | NCT06556810 IC14 for Treatment of Acute Decompensated Heart Failure | Acute Decompensated Heart Failure | completed | 10 |
| 2026-08-30 est. | P3 | Beletalent (Zhuhai) Pharmaceutical Co., Ltd | NCT06817265 Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy | Non-Proliferative Diabetic Retinopathy | recruiting | 360 |
| 2026-08-30 est. | P2 | TJ Biopharma Co., Ltd. | NCT07005336 A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Loca | Non Small Cell Lung Cancer | active not recruiting | 150 |
| 2026-08-30 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07108699 Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease (COPD) | active not recruiting | 180 |
| 2026-08-30 est. | P2 | Innovent Biologics Technology Limited (Shanghai R&D Center) | NCT07275840 A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD | Neovascular Age-related Macular Degeneration | recruiting | 800 |
| 2026-08-31 est. | P3 | AMAG Pharmaceuticals, Inc. | NCT03619850 A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Ped | Chronic Kidney Disease; Iron Deficiency Anemia | recruiting | 129 |
| 2026-08-31 | P3 | Idorsia Pharmaceuticals Ltd. | NCT03737214 A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease | Fabry Disease | completed | 107 |
| 2026-08-31 | P3 | Galderma R&D | NCT03989206 Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis | Moderate-to-Severe Atopic Dermatitis | completed | 1935 |
| 2026-08-31 est. | P3 | Daiichi Sankyo | NCT04704934 Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-C | Gastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | active not recruiting | 490 |
| 2026-08-31 est. | P1/P2 | Myrtelle Inc. | NCT04833907 rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease | Canavan Disease | enrolling by invitation | 24 |
| 2026-08-31 | P2/P3 | Lumen Bioscience, Inc. LUMN | NCT05330182 LMN-201 for Prevention of C. Difficile Infection Recurrence | Clostridioides Difficile Infection | active not recruiting | 375 |
| 2026-08-31 est. | P2 | Translational Sciences, Inc. | NCT05408546 Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial | Pulmonary Embolism | active not recruiting | 64 |
| 2026-08-31 est. | P2 | Kadmon, a Sanofi Company | NCT05567406 Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and F | Chronic Graft Versus Host Disease | withdrawn | |
| 2026-08-31 est. | P1/P2 | Verastem, Inc. VSTM | NCT05669482 Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | KRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neopla | active not recruiting | 40 |
| 2026-08-31 | P2 | Klus Pharma Inc. | NCT05816252 A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | Non-small Cell Lung Cancer | active not recruiting | 356 |
| 2026-08-31 | P3 | Cytokinetics CYTK | NCT06081894 A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | active not recruiting | 500 |
| 2026-08-31 est. | P3 | Sichuan Jishengtang Pharmaceutical Co., Ltd. | NCT06534723 Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney) | Alzheimer's Dementia | recruiting | 570 |
| 2026-08-31 est. | P3 | Santen Pharmaceutical Co., Ltd. | NCT06666855 A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China | Open Angle Glaucoma; Ocular Hypertension | active not recruiting | 345 |
| 2026-08-31 est. | P3 | mAbxience Research S.L. | NCT06687369 A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer | active not recruiting | 726 |
| 2026-08-31 est. | P2 | Nantong Bencao Quadriga Medical Technology Co. Ltd. | NCT06810804 A Phase IIa Study to Evaluate NBQ72S | Breast Cancer | recruiting | 10 |
| 2026-08-31 | P3 | Arthrosi Therapeutics | NCT06846515 Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) | Gout; Arthritis, Gouty; Hyperuricemia; Gout Chronic | completed | 866 |
| 2026-08-31 | P3 | ALK-Abelló A/S | NCT07060885 A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 | Allergic Rhinoconjunctivitis; Allergic Rhinitis | completed | 327 |
| 2026-08-31 est. | P3 | Daewon Pharmaceutical Co., Ltd. | NCT07168473 Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma | Perennial Allergic Rhinitis Accompanied by Asthma | recruiting | 274 |
| 2026-08-31 est. | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07171606 A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients | First-line Advanced NSCLC Patients | recruiting | 240 |
| 2026-08-31 | P2 | 4Moving Biotech | NCT07225829 A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis | Knee Osteoarthritis; Synovitis of Knee | completed | 130 |
| 2026-08-31 | P3 | Inozyme Pharma | NCT07473973 ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic R | terminated | 2 |
| 2026-08-31 | P3 | Daewon Pharmaceutical Co., Ltd. | NCT07931521 Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux Disease | Erosive Reflux Disease; GERD (Gastroesophageal Reflux Disease) | completed | 328 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.